普瑞博思辅助治疗新生儿高胆红素血症疗效观察

摘要:

目的 观察普瑞博思对新生儿高胆红素血症的治疗作用。方法 ８９ 例新生儿高胆红素血症患儿随机分为对照组和治疗组，治疗组在常规治疗的同时，加用普瑞博思混悬液０．２ ｍｇ／ｋｇ，每日３ 次口服，共７ ｄ。治疗前后分别监测血清胆红素水平。结果 治疗组胆红素日均下降值为５３．１８±２６ ．３８ μｍｏｌ／Ｌ，明显高于对照组的３５ ．８６±２ ．３６ μｍｏｌ／Ｌ（ Ｐ＜ ０．０１）。结论 普瑞博思用于治疗新生儿黄疸，可加速降低胆红素水平，明显缩短治疗时间。

Abstract:

Objective To evaluate the effects of prepuside on hyperbilirubinemia in newborns. Methods 89 neonatal infants with hyperbilirubinemia were divided randomly into the conventional and prepulside therapy groups. All the patients were administrated the same conventional treatment and only the patients in the prepulside group received prepulside at a dose of 0.2 mg/kg, 3 times per day for 7 days. Serum bilirubin levels were determined before and on the 7 th day after the start of treatment.Results Bilirubin levels decreased by an average of 53.18±22.36 μmol/L per day in the prepulside group and of 35.86±22.36 μmol/L per day in the conventional group (P<0.01).Conclusions Prepulside as a supplementary therapy in the treatment of neonatal hyperbilirubinemia promotes the decrease of serum bilirubin levels and shortens the course of treatment.